• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Bristol Myers Squibb

Illustration for Fierces Chutes  Ladders feature showing a blue city skyline with executives making career moves o
Biotech

BMS unites R&D as chief of research departs—Chutes & Ladders

BMS unites R&D as research chief departs. Summit cuts commercial team. OncoNano makes its CEO appointment permanent.
Donavyn Coffey , Marissa Russo Nov 13, 2026 8:30am
BMS ESMO Bristol Myers Squibb

BMS reunites R&D divisions under Massacesi as Plenge departs

Nov 12, 2026 8:16am
Bristol Myers Squibb booth at AACR 2026

BMS walks away from $80M neurodegeneration bet after phase 1

Oct 29, 2026 10:53am
ribbon colors awareness

BMS joins 3-year collab to boost cancer trial participation

Oct 27, 2026 5:00am
Bristol Myers Squibb booth at AACR 2026

BMS sheds light on patient death in CAR-T trial

Oct 26, 2026 7:00am
Bristol Myers Squibb 2026

ESMO: BMS’ Massacesi hails PD-L1xVEGF data as ‘very promising’

Oct 25, 2026 7:03pm

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings